Welcome to our dedicated page for Vor Biopharma SEC filings (Ticker: VOR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Vor Biopharma Inc. (Vor Bio) SEC filings page on Stock Titan provides streamlined access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Nasdaq Global Select Market issuer trading under the symbol VOR, Vor Bio reports on its clinical-stage biotechnology business focused on telitacicept, a dual BAFF/APRIL fusion protein being developed for serious autoimmune diseases.
Through this page, readers can review current and historical filings such as Forms 10‑K and 10‑Q for detailed discussions of risk factors, financial condition, and the status of telitacicept clinical programs, along with Form 8‑K reports describing material events. Recent 8‑K filings have covered topics including underwritten public offerings of common stock, a private placement with institutional investors, a reverse stock split, changes to equity incentive plans, and governance updates involving Board and executive appointments.
Vor Bio also uses 8‑K filings to furnish investor presentations and clinical data updates, for example webcasts and slide decks discussing late-breaking Phase 3 results for telitacicept in Sjögren’s disease and IgA nephropathy, as well as global development plans in generalized myasthenia gravis. Other filings, such as proxy statements (DEF 14A), describe stockholder proposals related to equity plans, warrant issuances, and capital structure changes.
On Stock Titan, these documents are complemented by AI-powered summaries that highlight key points from lengthy filings, helping users quickly understand how new financings, clinical milestones, or corporate actions may affect Vor Bio’s capital structure and development strategy. Investors can also locate information related to registered offerings on Form S‑3, at‑the‑market sales programs, and other registration statements referenced in the company’s 8‑K disclosures. This page is designed to make it easier to follow the regulatory record behind VOR, from financial reporting to telitacicept’s progress through late-stage development.
Vor Biopharma Inc. filed an S-8 registration to register an additional 8,761,334 shares of common stock for its employee benefit plans. The filing incorporates by reference prior S-8 filings and periodic reports including the annual report for the fiscal year ended December 31, 2024 and 10-Qs for March 31, 2025 and June 30, 2025. A schedule of exhibits lists charter and bylaw amendments, equity plans, legal opinion and auditor consents.
Vor Biopharma, Inc. files an S-3 shelf registration describing a license and commercialization arrangement, beneficial ownership and selling stockholder information, and an exhibit and incorporation-by-reference schedule. The company granted RemeGen an exclusive, perpetual and irrevocable license to exploit and manufacture Licensed Products in Greater China and received outside-territory know-how and a non-exclusive worldwide manufacturing license for use outside Greater China. Vor remains responsible for development, regulatory and commercialization activities and costs in the licensed territory and a joint steering committee will oversee the collaboration. The prospectus discloses multiple selling stockholders with specific share amounts being offered (examples include 16,000,000; 11,988,657 with 10,000,000 offered resulting in 29.0% post-offering for one holder) and footnotes describing voting and investment arrangements for RA Capital, VHCP entities, Qiming and NEXTBio-related parties. The filing lists exhibits including amended charter documents, bylaws, forms of securities agreements and legal and auditor consents.
ForGrowth III PA B.V., Forbion Growth Opportunities Fund III Cooperatief U.A. and Forbion Growth III Management B.V. report beneficial ownership related to pre-funded warrants to purchase 7,000,000 shares of Vor Biopharma Inc. common stock. The Warrants were acquired June 27, 2025 and became exercisable on September 18, 2025 upon satisfaction of certain conditions. The exercise price is $0.002 per share. Exercisability is subject to a 9.99% beneficial ownership limitation, and the percentage reported (9.99%) gives effect to that cap. Each Reporting Person reports shared voting and dispositive power over 7,000,000 shares and disclaims that this filing constitutes admission of group status. All Reporting Persons are organized in the Netherlands and list Forbion Capital Partners as their principal business address.
Vor Biopharma insiders report issuance and vesting of pre-funded warrants convertible into common stock. Reporting persons led by RA Capital entities and individuals Peter Kolchinsky and Rajeev Shah disclosed 10,000,000 pre-funded warrants that became exercisable on September 18, 2025; the warrants were originally acquired June 27, 2025 but were not exercisable until stockholder approval satisfied an exercisability condition. Each pre-funded warrant is exercisable for one share of common stock at a stated exercise price of $0.002, the warrants have no expiration date, and exercises are limited so aggregate ownership does not exceed 9.99% of outstanding common stock. Ms. Sarah Reed, General Counsel of the Adviser, serves on Vor's board.
RA Capital and affiliates report a 29.0% beneficial stake in Vor Biopharma (VOR) after a 1-for-20 reverse stock split. The reporting group’s position comprises 1,988,657 beneficially owned shares, including 1,891,035 shares held directly by RA Capital Healthcare Fund, warrants and a small number of optioned shares held for the adviser’s benefit. The filing notes that certain Pre-Funded Warrants and Common Stock Warrants are subject to Beneficial Ownership Blockers that prevent exercise above 9.99% ownership. Governance changes disclosed include the resignation of director Joshua Resnick and the appointment of Sarah Reed to the board.
Vor Biopharma Inc. (VOR) insiders reported a sale of common stock on 09/16/2025. Reprogrammed Interchange LLC executed multiple trades selling 447,278 shares at a weighted average price of $1.5401, with trade prices ranging from $1.52 to $1.58. After the reported sale, the amount of shares beneficially owned by Reprogrammed is 32,781,209 shares and the ownership is listed as direct. Reid Hoffman is separately reported as a director and may be deemed a beneficial owner of the shares held by Reprogrammed due to shared control and indirect pecuniary interest, though he disclaims beneficial ownership except to the extent of his pecuniary interest. The Form 4 was signed on 09/18/2025 by Reid Hoffman and Frank Huang, Manager of Reprogrammed Interchange LLC.
Vor Biopharma Inc. filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation to implement a 1-for-20 reverse stock split. The Charter Amendment was approved by stockholders at the Company’s Special Meeting of Stockholders on August 25, 2025 and the amendment was filed with the Delaware Secretary of State on September 17, 2025. The filing is signed by Jean-Paul Kress, Chief Executive Officer. No other corporate changes, financings, or forward-looking guidance are disclosed in the provided text.
Reprogrammed Interchange LLC and Reid Hoffman reported multiple open-market sales of Vor Biopharma (VOR) common stock in September 2025. The filing discloses three non-derivative sales: 284,805 shares sold on 09/11/2025 at a weighted average price of $1.8308, 300,000 shares sold on 09/12/2025 at $1.7541, and 400,000 shares sold on 09/15/2025 at $1.6408. Following the transactions, Reprogrammed held 33,228,487 shares on a direct basis. The form clarifies the prices are weighted averages from multiple trades and states that Reid Hoffman may be deemed a beneficial owner of shares held by Reprogrammed due to shared control, but he disclaims beneficial ownership except for his pecuniary interest.
Amendment No. 3 to a Schedule 13D discloses that Reprogrammed Interchange LLC and Reid Hoffman reduced their combined beneficial stake in Vor BioPharma Inc. through multiple open-market sales. The reporting persons now report beneficial ownership of 33,928,487 shares (26.8% of the class). The amendment details sales from August 25 through September 11, 2025, that together total 5,045,614 shares sold in the referenced transactions, executed at weighted average prices mostly around $1.82–$2.12 per share. The filing states the sales were in open market transactions and that there are no related contracts or arrangements with respect to the issuer’s securities.
The amendment is a disclosure of significant share disposition by the reporting persons and confirms continued shared voting and dispositive power over the reported shares.
Vor Biopharma insiders sold a substantial block of common stock over three days. Reprogrammed Interchange LLC reported three dispositions totaling 1,263,647 shares sold in multiple trades at weighted-average prices of $1.9897, $2.0004 and $1.8151. Reported post-transaction beneficial holdings held by Reprogrammed decreased from 35,012,518 to 34,213,292 shares across the reported transactions. The filing notes these shares are held by Reprogrammed Interchange LLC and that Reid Hoffman may be deemed an indirect beneficial owner by virtue of shared control and pecuniary interest, while disclaiming beneficial ownership except to the extent of any pecuniary interest.
FAQ
What is the current stock price of Vor Biopharma (VOR)?
What is the market cap of Vor Biopharma (VOR)?
